1. Sodium Bicarbonate Supplementation and Urinary TGF- β 1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial.
- Author
-
Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, and Beddhu S
- Subjects
- Aged, Aged, 80 and over, Biomarkers urine, Creatinine urine, Diabetes Mellitus, Type 1 diagnosis, Diabetes Mellitus, Type 2 diagnosis, Diabetic Nephropathies diagnosis, Diabetic Nephropathies etiology, Diabetic Nephropathies urine, Double-Blind Method, Female, Fibronectins urine, Hepatitis A Virus Cellular Receptor 1 metabolism, Humans, Lipocalin-2 urine, Male, Middle Aged, Sodium Bicarbonate adverse effects, Time Factors, Treatment Outcome, Utah, Veterans, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies drug therapy, Sodium Bicarbonate therapeutic use, Transforming Growth Factor beta1 urine
- Abstract
Background and Objectives: In early-phase studies of individuals with hypertensive CKD and normal serum total CO
2 , sodium bicarbonate reduced urinary TGF- β 1 levels and preserved kidney function. The effect of sodium bicarbonate on kidney fibrosis and injury markers in individuals with diabetic kidney disease and normal serum total CO2 is unknown., Design, Setting, Participants, & Measurements: We conducted a randomized, double-blinded, placebo-controlled study in 74 United States veterans with type 1 or 2 diabetes mellitus, eGFR of 15-89 ml/min per 1.73 m2 , urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g, and serum total CO2 of 22-28 meq/L. Participants received oral sodium bicarbonate (0.5 meq/kg lean body wt per day; n =35) or placebo ( n =39) for 6 months. The primary outcome was change in urinary TGF- β 1-to-creatinine from baseline to months 3 and 6. Secondary outcomes included changes in urinary kidney injury molecule-1 (KIM-1)-to-creatinine, fibronectin-to-creatinine, neutrophil gelatinase-associated lipocalin (NGAL)-to-creatinine, and UACR from baseline to months 3 and 6., Results: Key baseline characteristics were age 72±8 years, eGFR of 51±18 ml/min per 1.73 m2 , and serum total CO2 of 24±2 meq/L. Sodium bicarbonate treatment increased mean total CO2 by 1.2 (95% confidence interval [95% CI], 0.3 to 2.1) meq/L, increased urinary pH by 0.6 (95% CI, 0.5 to 0.8), and decreased urinary ammonium excretion by 5 (95% CI, 0 to 11) meq/d and urinary titratable acid excretion by 11 (95% CI, 5 to 18) meq/d. Sodium bicarbonate did not significantly change urinary TGF- β 1/creatinine (difference in change, 13%, 95% CI, -10% to 40%; change within the sodium bicarbonate group, 8%, 95% CI, -10% to 28%; change within the placebo group, -4%, 95% CI, -19% to 13%). Similarly, no significant effect on KIM-1-to-creatinine (difference in change, -10%, 95% CI, -38% to 31%), fibronectin-to-creatinine (8%, 95% CI, -15% to 37%), NGAL-to-creatinine (-33%, 95% CI, -56% to 4%), or UACR (1%, 95% CI, -25% to 36%) was observed., Conclusions: In nonacidotic diabetic kidney disease, sodium bicarbonate did not significantly reduce urinary TGF- β 1, KIM-1, fibronectin, NGAL, or UACR over 6 months., (Copyright © 2020 by the American Society of Nephrology.)- Published
- 2020
- Full Text
- View/download PDF